MK-2894 Sodium Salt - CAS# 1006036-88-9 4 2HCl Bristol-Myers Squibb introduced Gatifloxacin in

Bristol-Myers Squibb introduced Gatifloxacin in 1999 under the proprietary name Tequin for the treatment of respiratory tract infections

Prolonged treatment of cells with SSE15206 results in apoptotic cell death accompanied by p53 induction

Y15 decreases viability

InChiKey: LTWQQWSXYYXVGA-UHFFFAOYSA-N

4-dimethoxyphenyl)ethyl]amine hydrochloride

MK-2894 Sodium Salt - CAS# 1006036-88-9 4 2HCl Bristol-Myers Squibb introduced Gatifloxacin inMK 2894 is a potent and selective prostaglandin E2 subtype 4 receptor (PGE2) antagonist. MK 2894 exhibits favorable pharmacokinetic profile in a number of preclinical species and potent anti inflammatory activity in several animal models of pain inflammation. MK 2894 also shows favorable GI tolerability profile in rats when compared to traditional NSAID indomethacin. Product information CAS Number: 1006036 88 9 Molecular Weight: 495. 49 Formula: